Lilly/BI Report Success For Oral Diabetes Drug, Adjust Alliance
This article was originally published in The Pink Sheet Daily
Executive Summary
Eli Lilly and Boehringer Ingelheim announced positive top-line data for a quartet of pivotal trials of their SGLT-2 candidate empagliflozin, while Lilly now will be going it alone on LY2605541, a long-acting insulin.
You may also be interested in...
Nothing To SAVOR For Bristol/AZ From Onglyza Results
Bristol and AstraZeneca announced mixed results from a post-marketing study for their diabetes drug Onglyza that will likely have no commercial ramifications for the drug, which has been a disappointment since its launch in 2009.
Nothing To SAVOR For Bristol/AZ From Phase IV Results
Bristol and AstraZeneca announced mixed results from a post-marketing study for their diabetes drug Onglyza that will likely have no commercial ramifications for the drug, which has been a disappointment since its launch in 2009.
Merck And Pfizer Make A Late Play For The Diabetes Market
Two of the world’s largest pharmaceutical companies are teaming up to develop a treatment for type 2 diabetes, but the drug will have plenty of competitors with a better market position by the time it faces regulatory approval.